A Phase 2, Multicenter, Single-arm, Open-Label Study of Pomalidomide in Combination with Low Dose Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma Following Lenalidomide plus Dexamethasone in the Second Line Setting

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-4047-MM-014

To Learn More Call
201-510-0910